2′-Fluoro-2′-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705

Peifa Yu¹ · Yining Wang¹ · Yunlong Li¹ · Yang Li¹ · Zhijiang Miao¹ · Maikel P. Peppelenbosch¹ · Qiuwei Pan¹

Received: 23 March 2020 / Accepted: 30 June 2020 / Published online: 8 August 2020
© The Author(s) 2020

Abstract
Noroviruses are the main causative agents of acute viral gastroenteritis worldwide. However, no vaccine or specific antiviral treatment is available, imposing a heavy global health burden. The nucleoside analogue 2′-fluoro-2′-deoxycytidine (2′-FdC) has been reported to have broad antiviral activity. Here, we report that 2′-FdC significantly inhibits murine norovirus replication in macrophages. This effect was partially reversed by exogenous supplementation of cytidine triphosphate. The combination of 2′-FdC with mycophenolic acid, ribavirin or favipiravir (T705) exerts synergistic antiviral effects. These results indicate that 2′-FdC is a potential candidate for antiviral drug development against norovirus infection.

Introduction
Human norovirus (HuNV) is a non-enveloped, positive single-stranded RNA virus [1]. Recently, noroviruses have been classified into at least 10 genogroups (GI-GX) on the basis of the amino acid sequence diversity of the viral VP1 protein [2]. Viruses in the GI, GII, GIV, GVIII and GIX genogroups can infect humans and are a major cause of acute epidemic viral gastroenteritis worldwide [2]. It is estimated that noroviruses are responsible for 699 million gastroenteritis cases per year [3] and 200,000 deaths in children under 5 years of age in developing countries [4]. Although norovirus gastroenteritis is usually self-limiting, it has been recognized as an emerging burden in immunocompromised populations, particularly transplant recipients [5, 6]. However, research into HuNV infection has been hampered by the lack of availability of robust experimental models sustaining viral infection. Murine norovirus (MNV), which is capable of replicating in both cell culture and small-animal models, shares similar traits with HuNV in structural and genetic features and has thus been widely used as a surrogate model [7, 8]. To date, no vaccine or specific antiviral treatment is available, and clinical management is restricted to supportive care and oral rehydration. Thus, the development of specific antiviral drugs for norovirus infection is urgently needed.

Potential inhibitors of noroviruses have been identified, and some of these have demonstrated efficacy in experimental models. Ribavirin has been extensively studied and exhibits broad antiviral activity against multiple viruses, including hepatitis C virus (HCV) [9], hemorrhagic fever virus [10], hepatitis E virus [11, 12], and norovirus [13]. In a clinical study, ribavirin treatment resulted in complete viral clearance in a subset of norovirus-infected patients, but treatment failure occurred in two cases [14]. We demonstrated previously that mycophenolic acid (MPA), a potent inhibitor of IMP dehydrogenase (IMPDH), can inhibit norovirus replication in cell culture [15]. Favipiravir, also known as T-705, has been approved for the treatment of influenza in Japan and has been repositioned to treat patients with Ebola virus infection [16, 17]. It has been shown to be effective against noroviruses, but the treatment can induce mutagenesis in mice and in patients, challenging the application of favipiravir for treating chronic norovirus infection [18].

Recently, 2′-fluoro-2′-deoxycytidine (2′-FdC), also known as 2′-deoxy-2′-fluorocytidine, has been reported to exert broad antiviral activity against HCV, Lassa virus, Crimean-Congo hemorrhagic fever virus, and bunyaviruses [19–22]. Given the success of 2′-FdC against the
2'-FdC exerts anti-MNV activity in RAW264.7 cells. RAW264.7 cells were infected with MNV-1 at an MOI of 1 for 1 h, and the culture medium was replaced by medium containing different concentrations of 2'-FdC for 20 h. (A) The viral RNA level and (B) NS1/2 protein expression were analyzed by qRT-PCR (n = 6) and western blotting, respectively. (C) RAW264.7 cells were infected with MNV-1 at an MOI of 1 for 1 h, and the culture medium was replaced by medium containing different concentrations of 2'-FdC for 20 h. Viral NS1/2 protein expression was analyzed by confocal assay. (D) RAW264.7 cells were infected with MNV-1 at an MOI of 1 for 1 h and then left untreated or treated with 100 µM 2’-FdC for 20 h. The viral titer was determined by TCID_{50} assay (n = 6). RAW264.7 cells were infected with (E) MNV CW3 or (F) MNV CR8 at a MOI of 1 for 1 h and then left untreated or treated with 2’-FdC (10 µM and 100 µM, respectively) for 20 h. The viral RNA level and NS1/2 protein expression were analyzed by qRT-PCR (n = 6) and western blotting, respectively. (G) RAW264.7 cells were left uninfected or infected with MNV-1 at an MOI of 1 for 1 h and then left untreated or treated with different concentrations of 2’-FdC for 20 h. The 50% cytotoxic concentration (CC_{50}) (n = 16) and 50% inhibitory concentration (IC_{50}) (n = 4-6) against viral replication were calculated using GraphPad Prism 5 software. Data were normalized to the untreated control (set as 1). *, P < 0.05; **, P < 0.01. β-actin was used as a loading control. For immunoblot results (E and F), the band intensity of the NS1/2 protein in each lane was quantified using Odyssey software, and the quantification results were normalized to β-actin expression (control, set as 1).

Materials and methods

Reagents

2’-Fluoro-2’-deoxycytidine was purchased from Biosynth Carbosynth and dissolved in dimethyl sulfoxide (DMSO, Sigma, Zwijndrecht, The Netherlands). MPA (Sigma), ribavirin (Bio-Connect BV), T705 (BioVision), cytidine triphosphate (CTP; Sigma), guanosine triphosphate (GTP; Sigma), human IFN-α (Thermo Scientific, The Netherlands) and JAK inhibitor 1 (Santa Cruz Biotechnology, USA) were used. A rabbit polyclonal antiserum against MNV NS1/2 [23] was kindly provided by Prof. Vernon K. Ward (School of Biomedical Sciences, University of Otago, New Zealand), β-actin antibody (#sc-47778) was purchased from Santa Cruz Biotechnology. IRDye® 800CW-conjugated goat anti-rabbit and goat anti-mouse IgGs (Li-Cor Bioscience, Lincoln, USA) were used as secondary antibodies, as appropriate.

Cells and viruses

RAW264.7 and J774A.1 were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Lonza Verviers, Belgium) supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (FCS; Hyclone, Logan, UT, USA) and 100 µg of streptomycin, and 100 IU of penicillin per mL. The murine norovirus strain MNV-1 (MNV-1.CW1), the acutely cleared strain MNV CW3, and the persistent strain MNV CR8 were produced by consecutively inoculating the virus (kindly provided by Prof. Herbert Virgin, Department of Pathology and Immunology, Washington University School of Medicine) onto RAW264.7 cells [24]. Human Huh7 hepatocellular carcinoma cells harboring a genotype 1 HuNV replicon (HG23) were kindly provided by Dr. Kyeong-Ok Chang (Kansas State University) [25]. A neomycin resistance gene was engineered into ORF2, conferring HG23 resistance to neomycin. Gentamycin (G418; Gibco) was added to HG23 culture medium at 0.5 mg/mL for selection before experimentation.

Tcid_{50}

MNV was quantified using a 50% tissue culture infectious dose (TCID_{50}) assay. Briefly, tenfold dilutions of MNV were inoculated onto RAW264.7 cells grown in a 96-well tissue culture plate at 1,000 cells/well. The plate was incubated at 37°C for another 5 days, and each well was examined under a light microscope for a cytopathic effect (CPE). The TCID_{50} was calculated by using the Reed-Muench method.

Antiviral assay

The antiviral assay was initiated by inoculating RAW264.7 or J774A.1 cells with MNV at a multiplicity of infection (MOI) of 1. After 1 h of infection, cells were washed twice with phosphate-buffered saline (PBS) to remove free virus particles and then treated with the indicated compounds. For combination assays, RAW264.7 cells were infected with the virus for 1 h, and the medium was replaced with medium containing 2’-FdC, MPA, ribavirin, or T705, alone or in combination, at the indicated concentrations. After 20 h of treatment, total RNA, protein and the supernatant samples were collected and further analyzed by qRT-PCR, western blot and TCID_{50} assay, respectively.

qRT-PCR

Total RNA was isolated using a Macherey NucleoSpin RNA II Kit (Bioke, Leiden, The Netherlands) and quantified using a NanoDrop ND-1000 spectrophotometer (Wilmington, DE, USA). cDNA was synthesized from 500 ng of RNA using a cDNA synthesis kit (TaKaRa Bio, Inc., Shiga, Japan). The cDNA of all target genes was quantified by SYBR-Green-based (Applied Biosystems) real-time PCR on a StepOne-PlusTM System (Thermo Fisher Scientific LifeSciences) according to the manufacturer’s instructions. Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and murine aldehyde-3-phosphate dehydrogenase (GAPDH) and murine
Fig. 2 CTP, but not GTP, reverses 2'-FdC-mediated inhibition of MNV replication. RAW264.7 cells were infected with MNV-1 at an MOI of 1 for 1 h and then either left untreated or treated with 2'-FdC, CTP or combinations thereof at the indicated concentrations for 20 h. (A) Viral RNA and (B) NS1/2 protein expression were analyzed by qRT-PCR (n = 6) and western blotting, respectively. RAW264.7 cells were infected with MNV-1 at an MOI of 1 for 1 h and then left untreated or treated with 2'-FdC, GTP or combinations thereof at the indicated concentrations for 20 h. (C) Viral RNA and (D) NS1/2 protein expression were analyzed by qRT-PCR (n = 6) and western blotting, respectively. (E) RAW264.7 cells were infected with MNV-1 at an MOI of 1 for 1 h and then left untreated or treated with 2'-FdC (100 µM), CTP (100 µM), GTP (100 µM) or combinations thereof for 20 h. The viral titers were determined by TCID$_{50}$ assay (n = 4). Data were normalized to the untreated control (set as 1). *, P < 0.05; **, P < 0.01; ns, not significant. β-actin was used as a loading control. For immunoblot results (B and D), the band intensity of the NS1/2 protein in each lane was quantified using Odyssey software, and the quantification results were normalized to β-actin expression (control, set as 1)
GAPDH genes were used as reference genes to normalize gene expression. The relative expression of the target gene was calculated as $2^{-\Delta\Delta CT}$, where $\Delta\Delta CT = \Delta CT_{\text{sample}} - \Delta CT_{\text{control}}$ ($\Delta CT = CT_{\text{target gene}} - CT_{\text{GAPDH}}$). All primer sequences are listed in Supplementary Table 1.

**Western blot**

Cultured cells were lysed in Laemmli sample buffer containing 0.1 M DTT, heated for 5 min at 95 °C, and loaded onto a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel. After electrophoresis, the proteins were electrophoretically transferred to a polyvinylidene difluoride (PVDF) membrane (pore size, 0.45 μM; Invitrogen) for 2 h with an electric current of 250 mA. Subsequently, the membrane was blocked with a mixture of 2.5 mL of blocking buffer (Odyssey) and 2.5 mL of PBS containing 0.05% Tween 20 for 1 h, followed by overnight incubation with primary antibodies (1:1000) at 4 °C. The membrane was washed three times and then incubated with IRDye-conjugated secondary antibody (1:5000) for 1 h. After washing three times, protein bands were detected using an Odyssey 3.0 Infrared Imaging System (Li-Cor Biosciences).

**Confocal fluorescence microscopy**

RAW264.7 or J774A.1 cells infected with MNV-1 at an MOI of 1 for 1 h, and the culture medium was replaced by medium containing different concentrations of 2'-FdC in an 8-well chamber (cat. no. 80826; ibidi GmbH) for 20 h. The cells were fixed with 4% paraformaldehyde in PBS, permeabilized with 0.2% Triton X-100, blocked with 5% skim milk for 1 h, reacted with rabbit polyclonal antiserum against MNV NS1/2, and stained with 4',6-diamidino-2-phenylindole (DAPI). Secondary antibody anti-rabbit IgG (H+L), F(ab')2 fragment (Alexa Fluor® 488 conjugate) was used. Imaging was performed on a Leica SP5 confocal microscopy using a 63x oil objective.

**IC50 and CC50 calculation**

The 50% inhibitory concentration (IC50) value and 50% cytotoxic concentration (CC50) were calculated using the formula $Y_{\text{Bottom}} + (\text{Top-Bottom})/ (1 \times (\log IC50-X) \times \text{HillSlope})$ using GraphPad Prism 5 software (GraphPad Prism 5; GraphPad Software Inc., La Jolla, CA, USA).

**MTT assay**

Cells were seeded into 96-well tissue culture plates, and cell viability was assessed by adding 10 mM 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (Sigma, Zwijndrecht, The Netherlands). After 3 h, the medium was replaced with 100 μL of DMSO and was incubated at 37°C for 50 min. The absorbance at 490 nm was recorded using a microplate absorbance reader (Bio-Rad, CA, USA).

**Statistical analysis**

Data are presented as the mean ± SEM. Comparisons between groups were performed using the Mann-Whitney test in GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). Differences were considered significant at a P-value less than 0.05.

**Results and discussion**

To test the potential anti-norovirus activity of 2'-FdC, we used the murine norovirus as a surrogate model. We found that 2'-FdC significantly decreased the viral RNA and NS1/2 protein expression of MNV-1 in RAW264.7 cells, a murine macrophage cell line that is susceptible to MNV propagation (Fig. 1A and B). The inhibitory effect of this compound was confirmed, with decreased viral NS1/2 expression observable by confocal fluorescence microscopy (Fig. 1C). Moreover, the viral titer was found to decrease after treatment with 100 μM 2'-FdC (Fig. 1D). To further examine the antiviral effects, another murine macrophage cell line, J774A.1, was used, and a similar inhibitory effect of 2'-FdC on MNV-1 replication was observed, with decreased viral RNA and NS1/2 protein expression (Supplementary Fig. 1).

With 2'-FdC emerging as a potential anti-MNV candidate, we further evaluated its antiviral effect on two other MNV strains with distinct biological characteristics, the acutely cleared strain MNVcw3 and the persistent strain MNVcr6. Notably, 2'-FdC inhibited viral RNA replication and protein expression of both viral strains (Fig. 1E and F). In addition, the IC50 value of 2'-FdC against MNV-1 replication in RAW264.7 cells was 20.92 μM (Fig. 1G), and the CC50 of 2'-FdC in RAW264.7 cells was 1.768 mM (Fig. 1G). Moreover, we tested the antiviral effect of 2'-FdC on HuNV by using HG23 cells harboring an HuNV replicon and found moderate inhibition of viral replication (Supplementary Fig. 2).

Nucleoside analogues have been reported to induce an antiviral interferon response [13, 26]. Interferon-stimulated genes (ISGs) are considered the ultimate effectors against viral infection, but we found that 2'-FdC treatment did not significantly increase ISG expression (Supplementary Fig. 3A), and inhibition of viral RNA production by 2'-FdC was not affected by treatment with a JAK inhibitor (Supplementary Fig. 3B), suggesting that the antiviral effect of 2'-FdC does not require ISG induction. Theoretically, nucleoside analogues exert potential antiviral activity.
Because they bind to the viral RNA polymerase active site to impede viral replication. Since 2'-FdC is an analogue of cytidine and fluorine is isosteric with a hydroxyl group, chemical conversion of 2'-FdC to the corresponding 2'-FdC-triphosphate (FdCTP) results in a compound with antiviral activity against HCV, possibly targeting the viral NS5B enzyme [20]. Thus, we performed a competition assay by using CTP and GTP, which showed that CTP partially reversed the inhibitory effects of 2'-FdC on MNV replication, as reflected in viral RNA and protein levels (Fig. 2A and B) as well as the viral titers (Fig. 2D). In contrast, no significant effect of GTP on 2'-FdC-mediated inhibition of viral replication was observed (Fig. 2C and D). Interestingly, we found that both CTP and GTP decreased the viral RNA level and NS1/2 protein expression (Fig. 2A-D). It has been shown that MNV infection can induce viperin transcription in RAW264.7 cells [27], and viperin can convert CTP into 3'-deoxy-3',4'-didehydro-CTP (ddhCTP), which acts as a chain terminator of RNA-dependent RNA-polymerases and inhibits replication of Zika virus [28]. Moreover, exogenous CTP/GTP might complete with the endogenous CTP/GTP for MNV replication [29]. These results suggest a potential mechanism of action of 2'-FdC against MNV, and it needs to be investigated whether 2'-FdC exerts anti-MNV activity by targeting the viral replicase.

Since MPA, ribavirin, and T705 have been reported to have anti-norovirus activity, a combined treatment using 2'-FdC together with these compounds might be envisaged. To achieve better antiviral efficacy, we evaluated the combined antiviral effects of 2'-FdC with MPA by mathematical modeling using MacSynergy [30]. Surprisingly, the results showed a moderate synergistic antiviral effect (36.57 \( \mu \text{M}^2\%\)), which is greater than either 2'-FdC or MPA alone (Fig. 3A). Similar synergistic antiviral effects were observed when combining 2'-FdC with ribavirin (99.18 \( \mu \text{M}^2\%\)) or T705 (112.47 \( \mu \text{M}^2\%\)) (Fig. 3B and C). To confirm the predicted synergistic antiviral effects, we measured viral protein expression and viral titers by using high concentrations of the antivirals without major cytotoxicity (Fig. 3F). As shown in Fig. 3D and E, the viral NS1/2 protein expression and viral titers were further decreased when the antivirals were used in combination, supporting the synergistic antiviral effects of 2'-FdC with MPA, ribavirin, or T705 against MNV replication.

Despite their wide clinical application, the potential side effects or unintended off-target effects of nucleoside analogues should be considered. Induction of mutagenesis by T705 treatment in patients has raised questions for treating chronic norovirus infections [18]. Previous studies have reported that 2'-FdC exhibits delayed toxicity after prolonged exposure, and no adverse clinical effects were observed in rats and woodchucks after 90 days of treatment [20]. Several derivatives of 2'-FdC have shown promise as anti-HCV drugs with progress to clinical trials [31, 32]. However, due to their potential mitochondrial toxicity, the long-term adverse effects of treatment with 2'-deoxynucleoside analogues remains a concern [33]. Thus, although 2'-FdC is an interesting antiviral compound, its potential adverse effects as well as its combination with other compounds should be carefully evaluated in future studies.

In conclusion, 2'-FdC exerts potent anti-MNV effects in macrophages. Importantly, 2'-FdC acts synergistically with the well-known antivirals, including MPA, ribavirin, and T705. Although further studies are still required for evaluation of the antiviral effects of 2'-FdC or its derivatives against HuNV infection in robust models, our results suggest that 2'-FdC can serve as a potential backbone for anti-norovirus drug design.

Acknowledgements We gratefully acknowledge Prof. Herbert W. Vir-gin (Washington University, St Louis, MO, USA) for providing us the MNV-1 (MNV-1.CW1), MNV\(^{W}^{}\) and MNV\(^{O}^{}\), Dr. Kyeong-Ok Chang (Kansas State University, USA) for providing the HuNV replicon; Prof. Vernon K. Ward (School of Biomedical Sciences, University of Otago, New Zealand) for providing rabbit polyclonal antiserum against MNV NS1/2. This research was supported by the China Scholarship Council for funding PhD fellowships to P. Yu (no. 201708620177),
Compliance with ethical standards

Conflict of interest The authors declare no conflict of interest.

Human and animal rights statement This article does not contain any studies with human participants or animals performed by any of the authors and is in compliance with ethical standards for research.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Karst SM, Wobus CE, Goodfellow IG, Green KY, Virgin HW (2014) Advances in norovirus biology. Cell Host Microbiol 15:668–680
2. Chhabra P, de Graaf M, Parra GI, Chan MC, Green K, Martella V, Irazusta J, Kaul S, Kroll JS, Kuperman SH, et al. (2017) Antiviral activity of favipiravir against human noroviruses. Antiviral Res 136:9–18
3. Bartsch SM, Lopman BA, Owada S, Hall AJ, Lee BY (2016) Global economic burden of norovirus gastroenteritis. PLoS One 11:e0151219
4. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parish UD (2008) Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 14:1224–1231
5. Bok K, Green KY (2012) Norovirus gastroenteritis in immunocompromised populations. N Engl J Med 367:2126–2132
6. Ye X, Van JN, Munoz FM, Revell PA, Kozinetz CA, Krance RA, Atmar RL, Estes MK, Koo HL (2015) Noroviruses as a cause of diarrhea in immunocompromised pediatric hematopoietic stem cell and solid organ transplant recipients. Am J Transplant 15:1874–1881
7. Wobus CE, Karst SM, Thackray LB, Chang K-O, Sosnovtsev SV, Belliot G, Krug A, Mackenzie JM, Green KY, Virgin IHW (2004) Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol 2:e432
8. Wobus CE, Thackray LB, Virgin HW (2006) Murine norovirus: a model system to study norovirus biology and pathogenesis. J Virol 80:5104–5112
9. Doss W, Shiha G, Hassany M, Soliman R, Fouda R, Khairy M, Samir W, Hammad R, Kersey K, Jiang D (2015) Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63:581–585
10. Andrei G, De Clercq E (1993) Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res 22:45–75
11. Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, Gouttenoire J (2016) Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 150:82–85:e84
12. Qu C, Xu L, Yin Y, Peppelenbosch MP, Pan Q, Wang W (2017) Nucleoside analogue 2′-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin. Arch Virol 162:2989–2996
13. Dang W, Xu L, Ma B, Chen S, Yin Y, Chang KO, Peppelenbosch MP, Pan Q (2018) Nitzoxanide inhibits human norovirus replication and synergizes with ribavirin by activation of cellular antiviral response. Antimicrob Agents Chemother 62
14. Woodward JM, Okraina-Klotszas E, Cordero-Ng AY, Aravintan A, Bandoh BN, Liu H, Davies S, Zhang H, Stevenson P, Curran MD, Kumararatne D (2015) The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency. Am J Gastroenterol 110:320–327
15. Dang W, Yin Y, Wang Y, Wang W, Su J, Sprengers D, van der Laan IJW, Felczak K, Pankiewicz KW, Chang KO, Koopmans MPG, Metselaar HJ, Peppelenbosch MP, Pan Q (2017) Inhibition of calcineurin or IMP dehydrogenase exerts moderate to potent antiviral activity against norovirus replication. Antimicrob Agents Chemother 61
16. Pharmacopoeia J (2011) Pharmaceutical and Food Safety Bureau. Ministry of Health, Labour and Welfare, Tokyo, pp 1723–1724
17. Sissooko D, Laguenan C, Folkesson E, M’Lebing A-B, Beavogui A-H, Baize S, Camara A-M, Maes P, Shepherd S, Danet C (2016) Experimental treatment with favipiravir for Ebola Virus Disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in guinea. PLoS Med 13:e1001967–e1001967
18. Ruis C, Brown L-AK, Roy S, Atkinson C, Williams R, Burns SO, Yara-Romero E, Jacobs M, Goldstein R, Breuer J (2018) Mutagenesis in norovirus in response to favipiravir treatment. N Engl J Med 379:2173–2176
19. Smee DF, Jung K-H, Westover J, Bowen BB (2018) 2′-Fluoro-2′-deoxycytidine is a broad-spectrum inhibitor of bunyaviruses in vitro and in phleboviral disease mouse models. Antiviral Res 160:48–54
20. Stuyver LJ, McBrayer TR, Whaitaker T, Tarnish PM, Ramesh M, Lostia S, Cartee L, Shi J, Hobbs A, Schinazi RF (2004) Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2′-deoxy-2′-fluorocytidine. Antimicrob Agents Chemother 48:651–654
21. Welch SR, Guerrero LW, Chakrabarti AK, McMullan LK, Flint M, Bluemling GR, Painter GR, Nichol ST, Spiropoulou CF, Albariño CG (2016) Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antiviral Res 136:9–18
22. Welch SR, Scholte FE, Flint M, Chatterjee P, Nichol ST, Bergeron É, Spiropoulou CF (2017) Identification of 2′-deoxy-2′-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. Antiviral Res 147:91–99
23. Davies C, Brown CM, Westphal D, Ward JM, Ward VK (2015) Murine norovirus replication induces G0/G1 cell cycle arrest in asynchronously growing cells. J Virol 89:6057–6066
24. Wobus C, Karst S, Thackray L, Chang K, Sosnovtsev S, Belliot G, Krug A, Mackenzie J, Green K, Virgin H (2004) Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol 2:2076–2084
25. Chang K-O, Sosnovtsev SV, Belliot G, King AD, Green KY (2006) Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology 353:463–473
26. Luthra P, Naidoo J, Pietzsch CA, De S, Khadka S, Anantpadma M, Williams CG, Edwards MR, Davey RA, Bukreyev A (2018) Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses. Antiviral Res 158:288–302

27. Emmott E, Sorgeloos F, Caddy SL, Vashist S, Sosnovtsev S, Lloyd R, Heesom K, Locker N, Goodfellow I (2017) Norovirus-mediated modification of the translational landscape via virus and host-induced cleavage of translation initiation factors. Mol Cell Proteomics 16:S215–S229

28. Gizzi AS, Grove TL, Arnold JJ, Jose J, Jangra RK, Garforth SJ, Du Q, Cahill SM, Dulyaninova NG, Love JD (2018) A naturally occurring antiviral ribonucleotide encoded by the human genome. Nature 558:610–614

29. Jin Z, Tucker K, Lin X, Kao CC, Shaw K, Tan H, Symons J, Behera I, Rajwansi VK, Dyatkina N (2015) Biochemical evaluation of the inhibition properties of favipiravir and 2'C-methylcytidine triphosphates against human and mouse norovirus RNA polymerases. Antimicrob Agents Chemother 59:7504–7516

30. Prichard MN, Shipman C Jr (1990) A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14:181–205

31. Pierra C, Amador A, Benzaria S, Cretton-Scott E, d’Amours M, Mao J, Mathieu S, Moussa A, Bridges EG, Standring DN (2006) Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'C-methylcytidine. J Med Chem 49:6614–6620

32. Wedemeyer H, Jensen D, Herring R Jr, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J (2013) PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology 58:524–537

33. Arnold J, Sharma S, Feng J, Ray A, Smidansky E, Kireeva M, Cho A, Perry J, Vela J, Park Y (2012) Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog 8:e1003030

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.